LEXINGTON, Mass., March 5, 2018 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
and commercialization of innovative and effective therapeutics for
the treatment of cancer, today announced that Ali Fattaey, Ph.D., Curis's president and CEO,
will present at the Cowen & Company 38th Annual Health Care
Conference on Wednesday, March 14, 2018 at 8:00 a.m. EDT at the Boston Marriott Copley
Place.
A corresponding webcast of the presentation can be accessed by
visiting: http://wsw.com/webcast/cowen46/cris/.
The webcast will be archived shortly after the live event and
available for 90 days following the conference, and also available
on the Investor Relations section of the Curis website at
www.curis.com.
About Curis
Curis is a biotechnology company focused on the development and
commercialization of innovative and effective drug candidates for
the treatment of human cancers, including CUDC-907, which is being
investigated in clinical studies in patients with lymphomas and
solid tumors. Curis is also engaged in a broad collaboration with
Aurigene in the areas of immuno-oncology and precision oncology. As
part of this collaboration, Curis has exclusive licenses to oral
small molecule dual antagonists of PD1 and VISTA, including
PDL1/VISTA antagonist CA-170, and oral small molecule dual
antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327,
as well as to molecules designed to inhibit the IRAK4 kinase,
including CA-4948. CA-170 is currently undergoing testing in a
Phase 1 trial in patients with advanced solid tumors and
lymphomas. CA-4948 is currently undergoing testing in a Phase
1 trial in patients with lymphoma. Curis is also party to a
collaboration with Genentech, a member of the Roche Group, under
which Genentech and Roche are commercializing Erivedge® for the
treatment of advanced basal cell carcinoma. For more information,
visit Curis's website at www.curis.com.
View original
content:http://www.prnewswire.com/news-releases/curis-to-present-at-cowen--company-38th-annual-health-care-conference-300603209.html
SOURCE Curis, Inc.